Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps)

IF 0.2 Q4 DERMATOLOGY
Ayman Elgendi , Hanan Nada , Al Sadat Mosbeh , Mona Maatouk , Majdy Abulghany , Wayne Gulliver
{"title":"Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps)","authors":"Ayman Elgendi ,&nbsp;Hanan Nada ,&nbsp;Al Sadat Mosbeh ,&nbsp;Mona Maatouk ,&nbsp;Majdy Abulghany ,&nbsp;Wayne Gulliver","doi":"10.1016/j.jdds.2014.03.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Psoriasis is associated with a variety of psychological difficulties, including poor self-esteem, sexual dysfunction, anxiety, depression, and suicidal ideation.</p></div><div><h3>Objectives</h3><p>The aim of this study was to obtain further data on the extent of depression among psoriatic patients, the effectiveness of adalimumab treatment on the depression symptoms associated with psoriasis and to explore the association between improvement in depression symptoms and improvement in Psoriasis Area and Severity Index.</p></div><div><h3>Methods</h3><p>The effects of adalimumab (40<!--> <!-->mg every other week) on ZDS score and PASI at week 24 were assessed. Relationships between ZDS and PASI were assessed. Changes in ZDS score were compared for patients with and without a 75% or greater reduction in baseline PASI score. An improvement of 6 points or more in the Zung depression scale was considered a clinically meaningful improvement.</p></div><div><h3>Results</h3><p>Forty five Patients with moderate to severe psoriasis were assessed for depression symptoms at baseline and week 24 using the Zung Self-rating Depression Scale (ZDS). At month 6 after starting adalimumab, 80% of enrolled patients achieved 75% improvement in their PASI score (PASI75) at month 6 of adalimumab therapy and 97.8% achieved a meaningful improvement of Zung depression score (more than 6 points decline in the Zung depression score). Age at time of assessment significantly predicted depression (<em>p</em> <!-->=<!--> <!-->0∗030), with the younger age predicting a higher depression score (standard co-efficient -.451). Achieving PASI 75 could significantly predict improvement in depression (<em>p</em> <!-->=<!--> <!-->0.002, standard coefficient-.746).</p></div><div><h3>Conclusion</h3><p>Adalimumab may be associated with relief symptoms of depression in patients with moderate to severe psoriasis. Reductions in depression symptoms were significantly correlated with reductions in psoriasis severity.</p></div>","PeriodicalId":43409,"journal":{"name":"Journal of Dermatology & Dermatologic Surgery-JDDS","volume":"19 1","pages":"Pages 15-20"},"PeriodicalIF":0.2000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jdds.2014.03.005","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatology & Dermatologic Surgery-JDDS","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352241014000085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 9

Abstract

Background

Psoriasis is associated with a variety of psychological difficulties, including poor self-esteem, sexual dysfunction, anxiety, depression, and suicidal ideation.

Objectives

The aim of this study was to obtain further data on the extent of depression among psoriatic patients, the effectiveness of adalimumab treatment on the depression symptoms associated with psoriasis and to explore the association between improvement in depression symptoms and improvement in Psoriasis Area and Severity Index.

Methods

The effects of adalimumab (40 mg every other week) on ZDS score and PASI at week 24 were assessed. Relationships between ZDS and PASI were assessed. Changes in ZDS score were compared for patients with and without a 75% or greater reduction in baseline PASI score. An improvement of 6 points or more in the Zung depression scale was considered a clinically meaningful improvement.

Results

Forty five Patients with moderate to severe psoriasis were assessed for depression symptoms at baseline and week 24 using the Zung Self-rating Depression Scale (ZDS). At month 6 after starting adalimumab, 80% of enrolled patients achieved 75% improvement in their PASI score (PASI75) at month 6 of adalimumab therapy and 97.8% achieved a meaningful improvement of Zung depression score (more than 6 points decline in the Zung depression score). Age at time of assessment significantly predicted depression (p = 0∗030), with the younger age predicting a higher depression score (standard co-efficient -.451). Achieving PASI 75 could significantly predict improvement in depression (p = 0.002, standard coefficient-.746).

Conclusion

Adalimumab may be associated with relief symptoms of depression in patients with moderate to severe psoriasis. Reductions in depression symptoms were significantly correlated with reductions in psoriasis severity.

银屑病抑郁症:阿达木单抗治疗银屑病的相关缓解评估:观察性研究(DORADO - Ps)
背景牛皮癣与多种心理困难有关,包括自卑、性功能障碍、焦虑、抑郁和自杀意念。目的本研究的目的是获得银屑病患者抑郁程度的进一步数据,阿达木单抗治疗银屑病相关抑郁症状的有效性,并探讨抑郁症状的改善与银屑病面积和严重程度指数的改善之间的关系。方法观察阿达木单抗(40 mg / 2周)对第24周患者ZDS评分和PASI的影响。评估ZDS与PASI之间的关系。比较基线PASI评分降低75%及以上的患者ZDS评分的变化。Zung抑郁量表改善6分或以上被认为是有临床意义的改善。结果采用Zung抑郁自评量表(ZDS)对45例中重度银屑病患者在基线和第24周进行抑郁症状评估。在开始阿达木单抗治疗后的第6个月,80%的入组患者在阿达木单抗治疗的第6个月PASI评分(PASI75)改善了75%,97.8%的患者Zung抑郁评分有了显著改善(Zung抑郁评分下降超过6分)。评估时的年龄显著预测抑郁(p = 0 * 030),年龄越小抑郁评分越高(标准系数- 0.451)。PASI达到75可以显著预测抑郁症的改善(p = 0.002,标准系数- 0.746)。结论阿达木单抗可能与缓解中重度银屑病患者抑郁症状有关。抑郁症状的减轻与牛皮癣严重程度的减轻显著相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
17
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信